BioMed Research International / 2015 / Article / Fig 4

Research Article

S100B Inhibitor Pentamidine Attenuates Reactive Gliosis and Reduces Neuronal Loss in a Mouse Model of Alzheimer’s Disease

Figure 4

(a) Immunohistochemistry analysis showing the effect of pentamidine in hippocampal coronal sections after A injection. The upper panel shows GFAP-positive cells (astrocytes) infiltrating the hippocampi. Note the increased number of GFAP-positive cells in A-treated (2) compared to vehicle-treated mice (1) and the dose-dependent reduction after pentamidine treatment (3-4-5). Scale bar: 200 m. (b) Nissl staining showing the effect of pentamidine on pyramidal neuron loss in the CA1 area after A injection. Note the reduced number of neurons stained in A-treated (2) compared to vehicle-treated mice (1) and the dose-dependent reduction of neuronal loss after pentamidine treatment (3-4-5). Scale bar: 200 m. (c) Immunofluorescence analysis showing the effect of pentamidine in hippocampal coronal sections after A injection. Note the reduced number of neurons after A injection (2) compared to vehicle-treated mice (1) and the dose-dependent neuroprotection after pentamidine treatment (3-4-5). Scale bar: 200 m. (d) Relative quantification of GFAP expression, (e) extent of CA1 damage measurement, and (f) number of neurons stained with Fluorojade B (FJB) in the hippocampi. Results are expressed as mean ± SEM of experiments performed in triplicate. versus vehicle-treated mice; and versus A-treated mice.
(a)
(b)
(c)
(d)
(e)
(f)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.